KPV 10 MG

🧬 KPV Peptide — Research Overview

KPV (Lys‑Pro‑Val) is a tripeptide fragment derived from the C‑terminal end of alpha‑melanocyte‑stimulating hormone (α‑MSH). In research contexts, it is studied for its anti‑inflammatory, tissue‑protective, and antimicrobial properties without the hormonal or melanocortin activity associated with its parent molecule.

🔬 Mechanism of Action

• NF‑κB inhibition: KPV suppresses activation of NF‑κB, a key transcription factor that drives inflammatory cytokine production.

• MAPK pathway modulation: It dampens MAP kinase signaling, further reducing inflammatory cascades.

• PepT1 transport: During intestinal inflammation, PepT1 transporters are upregulated, allowing targeted uptake of KPV into affected tissue.

🧫 Research Applications

• Gastrointestinal inflammation models: Studies explore KPV’s ability to reduce cytokine levels and promote mucosal healing in colitis and IBD models.

• Dermatological research: Investigations focus on its potential to calm cytokine‑driven skin conditions such as eczema, psoriasis, and dermatitis.

• Mast‑cell and histamine regulation: KPV is evaluated for its role in stabilizing mast‑cell activity and mitigating histamine‑related responses.

• Wound healing and antimicrobial studies: Research indicates improved epithelial repair and activity against Staphylococcus aureus and Candida albicans.

⚖️ Research Status

KPV remains a research‑only compound not approved for human or veterinary use. Current investigations aim to clarify its pharmacokinetics, tissue specificity, and long‑term safety profile.